Novel HDAC6 inhibitor 1

Novel HDAC6 inhibitor 1 is an experimental small molecule inhibitor of histone deacetylase 6 (HDAC6) identified through a high-throughput screen of 9,600 compounds. Developed by researchers at Case Western Reserve University and University Hospitals - Seidman Cancer Center, it is designed to enhance proteasomal activity in malignant cells, specifically multiple myeloma and lymphoma. By increasing the generation of antigenic MHC class I peptides (such as the SIINFEKL complex), the compound boosts antigen presentation on the tumor cell surface, thereby triggering and enhancing CD8+ cytotoxic T lymphocyte (CTL)-mediated anti-tumor immunity. In preclinical studies, it demonstrated superior potency and faster kinetics in increasing proteasome activity compared to established HDAC6 inhibitors like Tubastatin-A and ricolinostat (ACY-1215), while maintaining low cytotoxicity.